Piper Jaffray Companies Comments on Neuronetics Inc’s FY2018 Earnings (STIM)
Neuronetics Inc (NASDAQ:STIM) – Stock analysts at Piper Jaffray Companies boosted their FY2018 earnings per share (EPS) estimates for shares of Neuronetics in a note issued to investors on Tuesday, November 6th. Piper Jaffray Companies analyst M. O’brien now forecasts that the company will earn ($1.66) per share for the year, up from their previous forecast of ($1.80). Piper Jaffray Companies currently has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Neuronetics’ Q2 2019 earnings at ($0.34) EPS, Q3 2019 earnings at ($0.32) EPS, Q4 2019 earnings at ($0.31) EPS, FY2019 earnings at ($1.29) EPS, Q1 2020 earnings at ($0.23) EPS, FY2020 earnings at ($1.02) EPS and FY2021 earnings at ($0.62) EPS.
Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, November 6th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.11. The firm had revenue of $13.74 million for the quarter, compared to the consensus estimate of $12.68 million.
Shares of NASDAQ STIM opened at $24.75 on Friday. Neuronetics has a twelve month low of $20.70 and a twelve month high of $39.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 7.63 and a quick ratio of 1.59.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Emerald Mutual Fund Advisers Trust bought a new stake in Neuronetics in the 2nd quarter valued at $1,570,000. Granahan Investment Management Inc. MA bought a new stake in Neuronetics in the 2nd quarter valued at $266,000. Wells Fargo & Company MN bought a new stake in Neuronetics in the 2nd quarter valued at $7,734,000. Schroder Investment Management Group bought a new stake in Neuronetics in the 2nd quarter valued at $4,374,000. Finally, Peregrine Capital Management LLC bought a new stake in Neuronetics in the 2nd quarter valued at $4,659,000. 60.76% of the stock is currently owned by institutional investors and hedge funds.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
See Also: Put Option
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.